AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

1 year ago

Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination…

CorMedix Inc. Announces New Commercial Agreement

1 year ago

BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic…

LifeMD Announces Major Enhancements to its Weight Management Program, Expanding Patient Access to Branded GLP-1 Therapies and Introducing New Treatment Options

1 year ago

Investments in pharmacy benefits infrastructure, in-home lab services and new treatment options expand platform capabilities and are estimated to increase…

NewVue Announces Strategic Partner Agreement with Konica Minolta Healthcare to Enhance Radiology Workflow

1 year ago

Exa Enterprise Imaging At RSNA 2023, Konica Minolta Healthcare introduces Exa Connect and Exa Clear Authorization as part of the…

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

1 year ago

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-beingNEW YORK, Sept. 19, 2024 (GLOBE…

Shock Top Announces its Official Craft Beer Sponsorship of University of Missouri Athletics

1 year ago

PORTLAND, Ore., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Today, The Shock Top Company, a subsidiary of Tilray Brands, Inc. (NASDAQ:…

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational

1 year ago

Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation…

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

1 year ago

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused…

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

1 year ago

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…